Robert Stevens
Technik-/Wissenschafts-/F&E-Leiter bei CorneaGen, Inc.
Profil
Robert J.
Stevens is currently working as the Senior Vice President-Research & Development at CorneaGen, Inc. He previously worked as a Director at Acucela, Inc. He completed his undergraduate and graduate degrees at the University of Washington.
Aktive Positionen von Robert Stevens
Unternehmen | Position | Beginn |
---|---|---|
CorneaGen, Inc.
CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ehemalige bekannte Positionen von Robert Stevens
Unternehmen | Position | Ende |
---|---|---|
ACUCELA INC | Direktor/Vorstandsmitglied | - |
Ausbildung von Robert Stevens
University of Washington | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
CorneaGen, Inc.
CorneaGen, Inc. Medical SpecialtiesHealth Technology CorneaGen, Inc. engages in the provision of cornea care services. It offers precision cut corneal tissue, Descemet’s Membrane Endothelial Keratoplasty, and Descemet’s Stripping Automated Endothelial Keratoplasty. The firm's products include EndoSerter, Geuder Glass Cannula, and Donor Trephine Punch. The company was founded in 2016 and is headquartered in Seattle, WA. | Health Technology |
Acucela, Inc.
Acucela, Inc. Pharmaceuticals: MajorHealth Technology Acucela, Inc. operates as a clinical-stage biotechnology company. It discovers and develops novel therapeutics to treat and show the progression of sight-threatening ophthalmic diseases. Its pipeline includes drug candidates and therapeutics for the treatment of age related macular degeneration, cataracts, presbyopia, diabetic retinopathy, retinitis igmentosa and Stargardt disease. The company was founded by Ryo Kubota in April 2002 and is headquartered in Seattle, WA. | Health Technology |